Tags: Do Math ProblemsLaser Engraving Business PlanCover Letters For Military SpousesPulphead Essays SummaryLifelong Learning EssaysCritical Essays On Edward AlbeeDissertation RomantismeWriting Definition Essay PowerpointInternational Assignment Services
Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Relationship of fasting and hourly blood glucose levels to Hb A1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes.
Injection-meal interval: recommendations of diabetologists and how patients handle it. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R.
Alterations of carbohydrate and lipoprotein metabolism in childhood obesity--impact of insulin resistance and acanthosis nigricans.
Felszeghy E, Kaposzta R, Juhasz E, Kardos L, Ilyes I.
The Merck Manuals: Online Medical Libraries: Diabetic ketoacidosis (DKA).
Hypoglycemia in patients with type 2 diabetes mellitus. Calles-Escandón J, Lovato LC, Simons-Morton DG, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH, Lispro Mixture-Glargine Study Group. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi I. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. An overview of the rationale for pharmacological strategies in type 2 diabetes: from the evidence to new perspectives. Insulin Pump Therapy: Guidelines for Successful Outcomes. Executive summary: Standards of medical care in diabetes--2010. Identifying variables associated with inaccurate self-monitoring of blood glucose: proposed guidelines to improve accuracy.